Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01835249 · ClinicalTrials.gov registry record · NA

Effect of Intense vs. Standard Hypertension Management on Nighttime Blood Pressure - an Ancillary Study to SPRINT

A NA study of Hypertension, sponsored by University of Minnesota.

Completed
Registry status
NA
Development phase
897
Enrollment target
10
Study locations

NCT01835249: Completed NA study of Hypertension, sponsored by University of Minnesota.

NCT01835249 is a NA study of Hypertension that has completed, run by University of Minnesota. The registered enrollment target is 897 participants, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (74% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01835249, a NA study of Hypertension, has completed, sponsored by University of Minnesota.

COMPLETED
Registry status
NA
Development phase
897 participants
Enrollment target
10
Study locations

Study Summary

Hypertension is a major risk factor for cardiovascular and renal disease, and a leading cause of premature mortality worldwide. Early hypertension studies showed that treating elevated blood pressure (BP) reduces patients' risk of cardiovascular disease and all-cause mortality. In subsequent research, patients achieved greater improvement in cardiovascular outcomes when their treatment was aimed at a moderate systolic BP target (\<150mmHg) than at higher targets. Although observational data suggest that even lower BP targets may be beneficial, this has not been seen in randomized trials; instead, "intense" treatment of hypertension (i.e., to a target systolic BP \<120mmHg) was found to have no effect on participants' risk for renal disease, cardiovascular disease, or all-cause mortality. One potential explanation for this apparent lack of benefit of intense BP targets is that the study protocols targeted reductions in clinic BP rather than ambulatory BP. Ambulatory BP monitoring (ABPM) allows for assessment of BP throughout the day and night. Of all the BP measurements, nighttime systolic BP appears to be the best predictor of cardiovascular disease and all-cause mortality. Because recent trials assessing intense BP targets did not include ambulatory BP measurements, the effect of intensive treatment on nighttime BP is largely unknown. To address this important gap in knowledge, we will conduct ABPM in 600 participants as part of an ancillary study to the ongoing Systolic Blood Pressure Intervention Trial (SPRINT). The goal of the ancillary study is to evaluate the effect of intensive vs. standard clinic based BP targets on nighttime BP (primary outcome), as well as night/day BP ratio, timing of peak BP, 24hr BP, and BP variability (secondary outcomes). The SPRINT trial includes approximately 9250 participants at high risk for cardiovascular disease. The investigators hypothesize that intense targeting of clinic systolic BP does not lower nighttime systolic BP co

Primary Outcome

Ambulatory blood pressure monitoring will be performed within 3 weeks of the 27 month follow up visit. For the primary analysis, nighttime BP will be defined by narrow clock time (01:00 AM to 6:00 AM).

Conditions Studied

Interventions

  • OTHER Intensive BP Arm
  • OTHER Standard BP arm

Study Locations (10)

Tennessee

  • Memphis VA - Memphis
  • Vanderbilt University - Nashville

Alabama

  • University of Alabama Birmingham - Birmingham

District of Columbia

  • Washington DC VA Medical Center - Washington D.C.

Florida

  • Mayo Clinic - Jacksonville

North Carolina

  • Carolinas Medical Center - Charlotte

Ohio

  • Louis Stokes Cleveland VA Medical Center - Cleveland

Pennsylvania

  • University of Pennsylvania - Philadelphia

Texas

  • Houston VA - Houston

Trial Details

FieldValue
Enrollment Target 897 participants
Start Date 2013-06
Est. Completion 2017-07
Phase NA
University of Minnesota

966 total trials

What the finished NCT01835249 record still lists

NCT01835249 is an interventional study that assigns participants to a tested intervention. The registered 897 participants enrollment target is mid-sized for trials with a published cap, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (74% lower).

The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Intensive BP Arm is the first listed.

NCT01835249 lists 10 locations in 9 states (Tennessee, Alabama, District of Columbia).

Frequently Asked Questions

What is clinical trial NCT01835249 about?

NCT01835249 is a clinical study titled "Effect of Intense vs. Standard Hypertension Management on Nighttime Blood Pressure - an Ancillary Study to SPRINT". Hypertension is a major risk factor for cardiovascular and renal disease, and a leading cause of premature mortality worldwide. Early hypertension studies showed that treating elevated blood pressure (BP) reduces patients' risk of cardiovascular disease and all-cause mortality. In subsequent researc...

What is the current status of trial NCT01835249?

This trial is currently completed. It is a NA study. The enrollment target is 897 participants. The study started on 2013-06. Estimated completion is 2017-07.

What conditions does trial NCT01835249 study?

This clinical trial studies the following conditions: Hypertension.

What interventions are being tested in trial NCT01835249?

The interventions under investigation include: Intensive BP Arm (OTHER), Standard BP arm (OTHER).

Who is sponsoring clinical trial NCT01835249?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01835249 being conducted?

This trial has 10 study locations across Alabama, District of Columbia, Florida, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01835249's enrollment target sits among peer trials

897 82nd of 470 higher than 389 of 470 other Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04862663 · 895 participants · Phase 3

    Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

  • NCT02352116 · 900 participants · NA

    Evaluation of Post-PACU Pain Management in Pediatric Surgery

  • NCT02414347 · 900 participants

    F 18 T807 Tau PET Imaging of Alzheimer's Disease

  • NCT02670408 · 900 participants

    Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01835249, the US trial registry maintained by the National Library of Medicine. NCT01835249 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.